GLP-1 Drugs May Lower Risk of Depression and Anxiety, Large Study Finds

A large study tracking nearly 100,000 people found that GLP-1 receptor agonists, including semaglutide sold under the brand names Ozempic and Wegovy, may lower the risk of depression and anxiety.

The research, reported in May 2026, adds to a growing body of evidence that these drugs have benefits beyond their original uses for type 2 diabetes and weight loss. Researchers tracked participants over an extended period and compared mental health outcomes between those taking GLP-1 drugs and those who were not.

The study found a statistically significant reduction in depression and anxiety diagnoses among GLP-1 users. Scientists believe the drugs may affect brain chemistry through pathways that regulate mood, appetite, and reward, though the exact mechanism is not yet fully understood.

Psychiatric Times covered the findings alongside other mental health research published in May 2026, noting that the results align with earlier, smaller studies suggesting a link between GLP-1 use and improved mood.

Researchers cautioned that the findings do not mean GLP-1 drugs should be prescribed specifically for depression or anxiety. The study was observational, meaning it identified an association rather than proving the drugs directly cause mental health improvements.

In a separate development, Ozempic became available in pill form for type 2 diabetes in May 2026, offering a lower-dose formulation for patients who prefer not to inject. A next-generation GLP-1 drug called survodutide also showed promising results in clinical trials, producing 16 percent more weight loss than existing options.

Mental Health Awareness Month, observed each May, provided additional context for the findings, with health organizations emphasizing the importance of accessible, evidence-based treatment options for the one in five adults living with a mental health condition.